Aprea Therapeutics News

Latest Aprea Therapeutics Stock News & APRE Headlines

Aprea Therapeutics, Inc. (NASDAQ:APRE) Stock Has Consensus Price Target of $2.80 According to Brokerages

5 days ago | defenseworld.net

Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

10 days ago | globenewswire.com

Aprea Therapeutics Announces Third Quarter 2026 Financial Results

12 days ago | globenewswire.com

Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology

a month ago | globenewswire.com

Aprea Therapeutics to Present at October Conferences

a month ago | globenewswire.com

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

3 months ago | globenewswire.com

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

5 months ago | globenewswire.com

Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know

6 months ago | zacks.com

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

6 months ago | globenewswire.com

Here Are Thursday’s Top Wall Street Analyst Research Calls: Alcoa, Chiron Real Estate, Clear Secure, Fortinet, Fresh Pet, Kennametal, Oracle, PayPal, United Therapeutics, and More

6 months ago | 247wallst.com

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

Market Closed

APRE

Aprea Therapeutics

$ 0.4162

-5.41%

Last 24H

Trading with leverage comes with a high risk and may not be suitable for everyone.

Portfolio

Updated 2 days ago

Top

Gainers

Losers

Symbol

Last Price

24H CNG

Aprea Therapeutics News

Latest Aprea Therapeutics Stock News & APRE Headlines

Download App

People Also Watch

Explore our Tools